What’s REALLY happening in the Roundup lawsuit battle

Key Concepts

• Roundup Weed Killer: A herbicide manufactured by Bayer, whose main ingredient is glyphosate.
• Glyphosate: The active ingredient in Roundup, alleged by some to cause cancer.
• Environmental Protection Agency (EPA): The U.S. agency responsible for environmental regulations, including the safety of pesticides.
• Solicitor General: The lawyer representing the U.S. government in Supreme Court cases.
• Litigation Overhang: The potential financial impact of ongoing lawsuits on a company.
• Carcinogenic: Capable of causing cancer.
• Prostate Cancer Drug: A successful pharmaceutical developed by Bayer.
• Menopausal Symptom Therapy: A non-hormonal treatment for symptoms like hot flashes.
• Tariffs: Taxes imposed on imported goods.

Bayer's Legal Battle Over Roundup

Supreme Court Review of Roundup Case

The transcript discusses a significant development for Bayer, the manufacturer of Roundup weed killer. The Office of the Solicitor General has formally backed Bayer's request for the Supreme Court to review its case concerning Roundup. This development has led to a jump in Bayer's shares, as much as 14%. The core of the litigation revolves around claims that the herbicide's main ingredient, glyphosate, causes cancer. Numerous juries have sided with plaintiffs over the past decade. Bayer acquired Roundup's manufacturer in 2018 for approximately $10 billion.

Solicitor General's Opinion and EPA's Stance

Solicitor General John Sauer stated in an opinion that the Environmental Protection Agency (EPA) has repeatedly determined that glyphosate is "not likely to be carcinogenic in humans." Furthermore, the EPA has approved Roundup for use with labels that do not include cancer warnings. This aligns with the EPA's findings under both Democratic and Republican administrations.

Impact on Farmers and Food Security

Bill Anderson emphasizes the importance of glyphosate for American farmers, consumers, and food security. He states that glyphosate is one of the most essential tools for weed control, estimating its impact on farming to be a 20% to 40% reduction in costs compared to techniques that do not utilize it. This makes it a "major tool for making healthy affordable food."

Global Regulatory Consensus on Glyphosate Safety

Anderson argues that the safety of glyphosate is not a political issue. He highlights that glyphosate has been tested and found safe by every major food and safety regulator worldwide, including the European Union, Japan, New Zealand, Australia, and Canada. The U.S. EPA has also repeatedly reached this conclusion under various administrations. The argument is that the findings of hundreds of scientists funded by taxpayer dollars to determine a product's safety should hold significant weight.

Bayer's Business Model and Mission

Anderson clarifies Bayer's historical business model, which includes producing medicines, consumer healthcare products, and agricultural inputs. The acquisition of Roundup's manufacturer was part of a strategy to create better situations for farmers. Bayer employs 87,000 people globally and is focused on "health for all and hunger for none." The ability to feed 8 billion people today, compared to struggling to feed 3.5 billion 40 years ago, is attributed to technological advancements, including products like Roundup that contribute to producing healthy and safe food.

Bayer's Pharmaceutical Innovations

Beyond agricultural products, Bayer has achieved significant successes in the pharmaceutical sector.

Prostate Cancer Drug

Bayer has developed a prostate cancer drug that is now the leading choice for newly diagnosed patients with metastatic prostate cancer, both in America and globally. Additional studies have been included in its label, demonstrating benefits in different stages of the disease and in combination therapies. This is a personal area of focus for Anderson, whose family has been impacted by prostate cancer.

Menopausal Symptom Therapy

Bayer has also launched a non-hormonal therapy for menopausal symptoms like hot flashes. This new option, available across America since last month, is for women who are not eligible for or choose not to take hormone therapy.

Bayer and Tariffs

Impact of Tariffs on Bayer

While Bayer is a German-based company, it has hundreds of operations, including many in the United States. Anderson states that tariffs have not had a significant effect on Bayer due to its diversified production across many countries, creating a balance.

Support for Fair Pricing of Pharmaceuticals

Bayer strongly supports the President's focus on ensuring that other developed countries pay their fair share for pharmaceuticals. The company agrees that Americans should not pay more for the same medicine than citizens of other developed nations. Anderson believes that if there are no increases in fair pricing from other countries, there will be less innovation in the pharmaceutical industry.

Conclusion

The transcript highlights a potential turning point for Bayer in its Roundup litigation, with the Solicitor General's support for Supreme Court review. It underscores the scientific consensus on glyphosate's safety, supported by global regulatory bodies and the EPA. The discussion also touches upon Bayer's contributions to food security through agricultural products and its advancements in pharmaceuticals, including a leading prostate cancer drug and a new non-hormonal therapy for menopausal symptoms. Finally, Bayer expresses support for fair international pricing of pharmaceuticals, emphasizing that increased innovation is contingent on equitable global contributions.